Research programme: neoantigen-based T cell therapeutics - Neon Therapeutics
Latest Information Update: 02 Mar 2016
At a glance
- Originator Neon Therapeutics
- Class CAR-T cell therapies
- Mechanism of Action Immunostimulants; T lymphocyte replacements
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer